Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational HighlightsRead More
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth ConferenceRead More
Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park CapitalRead More
Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X ConferenceRead More